A quick look at the investigational once-weekly shot that hits GLP-1, GIP and glucagon receptors, and how far along it is in development.
Recap by typeshit. Post by @revolution_med on Instagram.
Researchers are studying whether GLP-1 drugs, which act on mood, appetite and reward pathways, could help with depression, addiction and binge eating.
A retrospective cohort checks whether retinal disease started or worsened more in established users than in people never on either drug, plus a regional NAION review.
24:34
An animated explainer walking through what semaglutide does in the body, from appetite signals in the brain to digestion and blood sugar control.
A CHEST 2026 records analysis of roughly 2 million patients found 1.4% versus 2.3% at one year. The authors say it shows an association, not proof the drugs caused it.
The endocrinologist takes on the growing habit of taking GLP-1 drugs in small doses, in a piece written for Firstpost.
Piotr Alvarez and Nitish Sharma cover flow rate, temperature, dwell volume and TFA levels, and why robustness testing decides whether a method transfers cleanly.
Loading…